Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05838599 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | recruiting | Early Phase 1 | 25 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563023 | Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | not yet recruiting | Early Phase 1 | 6 | West China HospitalOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07546630 | Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT06735690 | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07548697 | A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04134325 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | active not recruiting | Early Phase 1 | 10 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06385652 | PET Imaging Study of 68Ga-NB381 in Multiple Myeloma | recruiting | Early Phase 1 | 30 | Peking University First HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03684980 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | active not recruiting | Early Phase 1 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06171152 | Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues | suspended | Early Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07376642 | A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Early Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia(M-HArbOr) | recruiting | Early Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT05294367 | Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma | recruiting | Early Phase 1 | 60 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07470073 | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults | recruiting | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06142396 | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | recruiting | Early Phase 1 | 30 | Augusta UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06890494 | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia | recruiting | Early Phase 1 | 3 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | suspended | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07429461 | Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia | recruiting | Early Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02356653 | Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC(ExpMACs) | recruiting | Early Phase 1 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma(SL4903) | not yet recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）(LB2505-0001) | not yet recruiting | Early Phase 1 | 38 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | terminated | Early Phase 1 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05800405 | Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Early Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05895994 | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | completed | Early Phase 1 | 2 | MEI HENGOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05921253 | Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy(OU-SCC-NCAN) | recruiting | Early Phase 1 | 104 | University of OklahomaOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07362602 | Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies | not yet recruiting | Early Phase 1 | 47 | The 923rd Hospital of Joint Logistics Support Force of People's Liberation ArmyOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07362732 | Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection | not yet recruiting | Early Phase 1 | 20 | Sichuan UniversityOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | not yet recruiting | Early Phase 1 | 3 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT06731504 | HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT | recruiting | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT01269593 | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | active not recruiting | Early Phase 1 | 63 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07336823 | JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07335094 | A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy | not yet recruiting | Early Phase 1 | 60 | Zhujiang HospitalOTHER | 0 | Jan 12, 2026 | clinicaltrials |
| NCT04514029 | Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel | active not recruiting | Early Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07322159 | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 7, 2026 | clinicaltrials |
| NCT06514768 | JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) | recruiting | Early Phase 1 | 20 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04370483 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma(CC-220) | active not recruiting | Early Phase 1 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | recruiting | Early Phase 1 | 19 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07131254 | A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors | recruiting | Early Phase 1 | 34 | Grit BiotechnologyINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03631043 | Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials